CL2021002152A1 - Métodos para tratar el dolor de la superficie ocular - Google Patents

Métodos para tratar el dolor de la superficie ocular

Info

Publication number
CL2021002152A1
CL2021002152A1 CL2021002152A CL2021002152A CL2021002152A1 CL 2021002152 A1 CL2021002152 A1 CL 2021002152A1 CL 2021002152 A CL2021002152 A CL 2021002152A CL 2021002152 A CL2021002152 A CL 2021002152A CL 2021002152 A1 CL2021002152 A1 CL 2021002152A1
Authority
CL
Chile
Prior art keywords
ocular surface
methods
treating ocular
surface pain
treating
Prior art date
Application number
CL2021002152A
Other languages
English (en)
Spanish (es)
Inventor
Quintus Medley
Muneto Mogi
Michela Montecchi-Palmer
Kalliopi Stasi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021002152A1 publication Critical patent/CL2021002152A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2021002152A 2019-02-15 2021-08-13 Métodos para tratar el dolor de la superficie ocular CL2021002152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962806682P 2019-02-15 2019-02-15

Publications (1)

Publication Number Publication Date
CL2021002152A1 true CL2021002152A1 (es) 2022-04-18

Family

ID=69740423

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002152A CL2021002152A1 (es) 2019-02-15 2021-08-13 Métodos para tratar el dolor de la superficie ocular

Country Status (17)

Country Link
US (4) US20200261456A1 (https=)
EP (1) EP3923909A1 (https=)
JP (2) JP7571037B2 (https=)
KR (1) KR20210129677A (https=)
CN (1) CN113453686B (https=)
AU (2) AU2020222348B2 (https=)
BR (1) BR112021015998A2 (https=)
CA (1) CA3130038A1 (https=)
CL (1) CL2021002152A1 (https=)
IL (1) IL284629A (https=)
JO (1) JOP20210217A1 (https=)
MX (2) MX2021009702A (https=)
PH (1) PH12021551968A1 (https=)
SG (1) SG11202107260VA (https=)
TW (2) TW202515576A (https=)
WO (1) WO2020165838A1 (https=)
ZA (1) ZA202104593B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
WO2022029656A1 (en) * 2020-08-06 2022-02-10 Novartis Ag Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
CN119184616A (zh) * 2024-09-03 2024-12-27 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) 一种疼痛等级的测评方法及其评估系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US7893260B2 (en) 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
BRPI0620264A2 (pt) 2005-12-22 2011-11-08 Prolexys Pharmaceuticals Inc quinazolonas aril-substituìdas e sua utilização
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
AR067631A1 (es) 2007-07-18 2009-10-21 Novartis Ag Combinaciones sinergicas de antagonistas de vr-1 e inhibidores de cox-2 , composicion farmaceutica y uso
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
CA2707441A1 (en) 2008-01-09 2009-07-16 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
CN109790116B (zh) 2016-09-20 2022-10-28 葛兰素史密斯克莱知识产权（第2 号）有限公司 Trpv4拮抗剂
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP2022520410A (ja) * 2019-02-15 2022-03-30 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤

Also Published As

Publication number Publication date
AU2020222348A1 (en) 2021-08-05
BR112021015998A2 (pt) 2021-10-05
ZA202104593B (en) 2025-03-26
JP2022520832A (ja) 2022-04-01
JP2025004186A (ja) 2025-01-14
IL284629A (en) 2021-08-31
US20210275529A1 (en) 2021-09-09
TW202515576A (zh) 2025-04-16
CN113453686A (zh) 2021-09-28
PH12021551968A1 (en) 2022-05-23
JP7571037B2 (ja) 2024-10-22
TW202045179A (zh) 2020-12-16
WO2020165838A9 (en) 2021-03-18
KR20210129677A (ko) 2021-10-28
AU2023203716B2 (en) 2025-03-20
US20220193078A1 (en) 2022-06-23
MX2021009702A (es) 2021-09-14
SG11202107260VA (en) 2021-08-30
US20240342174A1 (en) 2024-10-17
TWI878266B (zh) 2025-04-01
MX2025000353A (es) 2025-02-10
EP3923909A1 (en) 2021-12-22
CN113453686B (zh) 2025-04-15
US11234982B2 (en) 2022-02-01
JOP20210217A1 (ar) 2023-01-30
WO2020165838A1 (en) 2020-08-20
AU2020222348B2 (en) 2023-03-16
US20200261456A1 (en) 2020-08-20
CA3130038A1 (en) 2020-08-20
AU2023203716A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
CO2021010689A2 (es) Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrilo
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
NI202100029A (es) 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav 1.8
CL2021002152A1 (es) Métodos para tratar el dolor de la superficie ocular
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CU20200014A7 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
IL281773A (en) Ophthalmic composition for treatment of dry eye disease
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2020004405A (es) Compuestos biciclicos en puente como moduladores del receptor farnesoide x.
ECSP21080096A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CL2020000855A1 (es) Anticuerpos monoclonales anti-trkb y métodos de uso.
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
JOP20200304A1 (ar) مركبات بنزينسلفوناميد واستخدامها كعوامل علاجية
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
EA202190576A1 (ru) Полиморфные соединения и их применение
EP4021432A4 (en) ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
EA202190590A1 (ru) Соединения и способы лечения грибковых инфекций
CL2023002236A1 (es) Métodos para tratar la amiloidosis primaria
EA202190523A1 (ru) Замещенные индолы и способы их применения